AAPL331.90-6.42 (-1.90%) ▼|ABBV286.00-2.84 (-0.98%) ▼|ABT109.40-0.76 (-0.69%) ▼|ACN254.56-6.38 (-2.45%) ▼|ADBE246.14-5.33 (-2.12%) ▼|AMAT381.92+7.39 (+1.97%) ▲|AMD483.90+17.06 (+3.65%) ▲|AMGN461.26-4.19 (-0.90%) ▼|AMT187.29-1.01 (-0.54%) ▼|AMZN250.69+5.06 (+2.06%) ▲|AVGO332.13+9.90 (+3.07%) ▲|AXP325.50-2.48 (-0.76%) ▼|BA173.31-2.09 (-1.19%) ▼|BAC49.66+0.09 (+0.18%) ▲|BKNG155.67+1.92 (+1.25%) ▲|BLK1,161.32-5.83 (-0.50%) ▼|BMY61.71-1.31 (-2.08%) ▼|BNY149.31+1.53 (+1.04%) ▲|BRK-B557.07+0.96 (+0.17%) ▲|C122.71-0.39 (-0.32%) ▼|CAT623.94+10.32 (+1.68%) ▲|CL95.62-1.81 (-1.86%) ▼|CMCSA23.67-0.20 (-0.84%) ▼|COF208.71-2.06 (-0.98%) ▼|COP144.40-2.44 (-1.66%) ▼|COST1,019.26-21.29 (-2.05%) ▼|CRM222.20-3.98 (-1.76%) ▼|CSCO102.97+1.36 (+1.34%) ▲|CVS91.41+2.90 (+3.28%) ▲|CVX225.27-2.50 (-1.10%) ▼|DE665.83-1.77 (-0.27%) ▼|DHR230.11+2.14 (+0.94%) ▲|DIS114.18+1.07 (+0.95%) ▲|DUK126.51-1.87 (-1.46%) ▼|EMR166.39+0.43 (+0.26%) ▲|FDX318.02-0.23 (-0.07%) ▼|GD374.50+1.04 (+0.28%) ▲|GE320.67+4.89 (+1.55%) ▲|GEV918.20+55.95 (+6.49%) ▲|GILD167.47-2.86 (-1.68%) ▼|GM88.34-1.60 (-1.78%) ▼|GOOG278.27+0.23 (+0.08%) ▲|GOOGL280.03+1.04 (+0.37%) ▲|GS896.09-2.63 (-0.29%) ▼|HD333.66-7.49 (-2.20%) ▼|HON224.05+0.28 (+0.13%) ▲|IBM250.04-2.47 (-0.98%) ▼|INTC60.55+0.58 (+0.97%) ▲|INTU344.72-7.38 (-2.10%) ▼|ISRG440.75+3.88 (+0.89%) ▲|JNJ266.17-4.39 (-1.62%) ▼|JPM337.98-2.60 (-0.76%) ▼|KO94.80-1.03 (-1.07%) ▼|LIN511.55-8.17 (-1.57%) ▼|LLY1,409.38-1.61 (-0.11%) ▼|LMT639.00-4.15 (-0.65%) ▼|LOW213.38-4.77 (-2.19%) ▼|LRCX230.72+3.16 (+1.39%) ▲|MA647.18-10.92 (-1.66%) ▼|MCD263.04-2.60 (-0.98%) ▼|MDLZ65.12-1.26 (-1.90%) ▼|MDT98.88-0.41 (-0.41%) ▼|META621.03+14.30 (+2.36%) ▲|MMM177.05-1.31 (-0.73%) ▼|MO76.94-0.23 (-0.30%) ▼|MRK144.67-3.69 (-2.49%) ▼|MS186.09+0.36 (+0.19%) ▲|MSFT520.99+13.87 (+2.74%) ▲|MU855.10+21.51 (+2.58%) ▲|NEE84.33-0.70 (-0.82%) ▼|NFLX63.42+1.08 (+1.73%) ▲|NKE38.48-0.64 (-1.64%) ▼|NOW109.16+3.15 (+2.97%) ▲|NVDA206.69+4.63 (+2.29%) ▲|ORCL126.19+6.97 (+5.85%) ▲|PEP137.27-3.15 (-2.24%) ▼|PFE30.00-0.67 (-2.18%) ▼|PG162.06-1.50 (-0.92%) ▼|PLTR175.40-2.94 (-1.65%) ▼|PM208.03-0.26 (-0.12%) ▼|QCOM164.43+2.35 (+1.45%) ▲|RTX203.82+1.03 (+0.51%) ▲|SBUX104.77+0.37 (+0.35%) ▲|SCHW89.28+0.57 (+0.64%) ▲|SO93.75-0.86 (-0.91%) ▼|SPG222.08+0.35 (+0.16%) ▲|T21.39-0.05 (-0.23%) ▼|TMO698.34+15.69 (+2.30%) ▲|TMUS154.41-5.74 (-3.58%) ▼|TSLA398.50-5.32 (-1.32%) ▼|TXN312.49+10.47 (+3.47%) ▲|UBER66.60-0.11 (-0.16%) ▼|UNH404.44+4.00 (+1.00%) ▲|UNP303.43-3.57 (-1.16%) ▼|UPS109.17-0.54 (-0.49%) ▼|USB59.89-0.60 (-0.99%) ▼|V420.42-5.09 (-1.20%) ▼|VZ45.24+0.19 (+0.42%) ▲|WFC85.53-0.36 (-0.42%) ▼|WMT124.86-2.83 (-2.22%) ▼|XOM177.46-2.21 (-1.23%) ▼|AAPL331.90-6.42 (-1.90%) ▼|ABBV286.00-2.84 (-0.98%) ▼|ABT109.40-0.76 (-0.69%) ▼|ACN254.56-6.38 (-2.45%) ▼|ADBE246.14-5.33 (-2.12%) ▼|AMAT381.92+7.39 (+1.97%) ▲|AMD483.90+17.06 (+3.65%) ▲|AMGN461.26-4.19 (-0.90%) ▼|AMT187.29-1.01 (-0.54%) ▼|AMZN250.69+5.06 (+2.06%) ▲|AVGO332.13+9.90 (+3.07%) ▲|AXP325.50-2.48 (-0.76%) ▼|BA173.31-2.09 (-1.19%) ▼|BAC49.66+0.09 (+0.18%) ▲|BKNG155.67+1.92 (+1.25%) ▲|BLK1,161.32-5.83 (-0.50%) ▼|BMY61.71-1.31 (-2.08%) ▼|BNY149.31+1.53 (+1.04%) ▲|BRK-B557.07+0.96 (+0.17%) ▲|C122.71-0.39 (-0.32%) ▼|CAT623.94+10.32 (+1.68%) ▲|CL95.62-1.81 (-1.86%) ▼|CMCSA23.67-0.20 (-0.84%) ▼|COF208.71-2.06 (-0.98%) ▼|COP144.40-2.44 (-1.66%) ▼|COST1,019.26-21.29 (-2.05%) ▼|CRM222.20-3.98 (-1.76%) ▼|CSCO102.97+1.36 (+1.34%) ▲|CVS91.41+2.90 (+3.28%) ▲|CVX225.27-2.50 (-1.10%) ▼|DE665.83-1.77 (-0.27%) ▼|DHR230.11+2.14 (+0.94%) ▲|DIS114.18+1.07 (+0.95%) ▲|DUK126.51-1.87 (-1.46%) ▼|EMR166.39+0.43 (+0.26%) ▲|FDX318.02-0.23 (-0.07%) ▼|GD374.50+1.04 (+0.28%) ▲|GE320.67+4.89 (+1.55%) ▲|GEV918.20+55.95 (+6.49%) ▲|GILD167.47-2.86 (-1.68%) ▼|GM88.34-1.60 (-1.78%) ▼|GOOG278.27+0.23 (+0.08%) ▲|GOOGL280.03+1.04 (+0.37%) ▲|GS896.09-2.63 (-0.29%) ▼|HD333.66-7.49 (-2.20%) ▼|HON224.05+0.28 (+0.13%) ▲|IBM250.04-2.47 (-0.98%) ▼|INTC60.55+0.58 (+0.97%) ▲|INTU344.72-7.38 (-2.10%) ▼|ISRG440.75+3.88 (+0.89%) ▲|JNJ266.17-4.39 (-1.62%) ▼|JPM337.98-2.60 (-0.76%) ▼|KO94.80-1.03 (-1.07%) ▼|LIN511.55-8.17 (-1.57%) ▼|LLY1,409.38-1.61 (-0.11%) ▼|LMT639.00-4.15 (-0.65%) ▼|LOW213.38-4.77 (-2.19%) ▼|LRCX230.72+3.16 (+1.39%) ▲|MA647.18-10.92 (-1.66%) ▼|MCD263.04-2.60 (-0.98%) ▼|MDLZ65.12-1.26 (-1.90%) ▼|MDT98.88-0.41 (-0.41%) ▼|META621.03+14.30 (+2.36%) ▲|MMM177.05-1.31 (-0.73%) ▼|MO76.94-0.23 (-0.30%) ▼|MRK144.67-3.69 (-2.49%) ▼|MS186.09+0.36 (+0.19%) ▲|MSFT520.99+13.87 (+2.74%) ▲|MU855.10+21.51 (+2.58%) ▲|NEE84.33-0.70 (-0.82%) ▼|NFLX63.42+1.08 (+1.73%) ▲|NKE38.48-0.64 (-1.64%) ▼|NOW109.16+3.15 (+2.97%) ▲|NVDA206.69+4.63 (+2.29%) ▲|ORCL126.19+6.97 (+5.85%) ▲|PEP137.27-3.15 (-2.24%) ▼|PFE30.00-0.67 (-2.18%) ▼|PG162.06-1.50 (-0.92%) ▼|PLTR175.40-2.94 (-1.65%) ▼|PM208.03-0.26 (-0.12%) ▼|QCOM164.43+2.35 (+1.45%) ▲|RTX203.82+1.03 (+0.51%) ▲|SBUX104.77+0.37 (+0.35%) ▲|SCHW89.28+0.57 (+0.64%) ▲|SO93.75-0.86 (-0.91%) ▼|SPG222.08+0.35 (+0.16%) ▲|T21.39-0.05 (-0.23%) ▼|TMO698.34+15.69 (+2.30%) ▲|TMUS154.41-5.74 (-3.58%) ▼|TSLA398.50-5.32 (-1.32%) ▼|TXN312.49+10.47 (+3.47%) ▲|UBER66.60-0.11 (-0.16%) ▼|UNH404.44+4.00 (+1.00%) ▲|UNP303.43-3.57 (-1.16%) ▼|UPS109.17-0.54 (-0.49%) ▼|USB59.89-0.60 (-0.99%) ▼|V420.42-5.09 (-1.20%) ▼|VZ45.24+0.19 (+0.42%) ▲|WFC85.53-0.36 (-0.42%) ▼|WMT124.86-2.83 (-2.22%) ▼|XOM177.46-2.21 (-1.23%) ▼|
14 C
New York
Wednesday, November 4, 2026

Tag: programs

newsFORsourcecompanycontentinformationreleases1market

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE

Snow Caps THCA Flower – Extra Frosty Exotic Cannabis Strains Now Available for Sale

Las Vegas, NV, July 03, 2025 (GLOBE NEWSWIRE) -- Area 52, a vanguard in cannabinoid science and botanical engineering, today announced the debut of its 2025 THCA Snow Caps collection, a groundbreaking line of premium hemp flower completely enveloped in pure THCA diamonds. Engineered to “Alienize Your Mind,” these crystalline-coated buds represent a new frontier in potency and sensory experience for the discerning cannabis connoisseur.

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

NeuroEnergizer 2025 Update Positions OTC Audio Program at Forefront of Cognitive Wellness Movement

Binaural beat-based audio suite supports focus, rest, and digital clarity with a non-invasive, non-clinical format—now updated for 2025. 
Binaural beat-based audio suite supports focus, rest, and digital clarity with a non-invasive, non-clinical format—now updated for 2025.

March of Dimes Statement on the Passage of H.R. 1

ARLINGTON, Va., July 3, 2025 /PRNewswire-HISPANIC PR WIRE/ -- The passage of H.R. 1, the "One Big Beautiful Bill Act," sets in motion harmful...

Neuro Balance Therapy Update: Strongest Non-Clinical Reflex Routine for Seniors Concerned About Instability

New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+ 
New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+

March of Dimes Statement on the Passage of H.R. 1

ARLINGTON, Va., July 3, 2025 /PRNewswire/ -- The passage of H.R. 1, the "One Big Beautiful Bill Act," sets in motion harmful changes to...

Techy Acquires NerdsToGo, Expanding Its Tech Franchise Powerhouse

Strategic acquisition unites two industry leaders to create a comprehensive tech support service network. FORT LAUDERDALE, Fla., July 3, 2025 /PRNewswire/ -- Techy, a global...

NAMI Statement on Final Passage of Bill Cutting Medicaid for Millions of Americans

Hundreds of billions of dollars in cuts to the Medicaid program will be devastating for mental health care ARLINGTON, Va., July 3, 2025 /PRNewswire/ --...

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sienna Announces Second Quarter 2025 Results Release Date and Conference Call

MARKHAM, Ontario, July 03, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its 2025 second quarter results after market close on Tuesday, August 12, 2025. Nitin Jain, President and Chief Executive Officer, and David Hung, Chief Financial Officer and Executive Vice President, Investments, will host a conference call for the investment community the following day, Wednesday, August 13, 2025 at 10:00 a.m. (ET).

Daughters of the American Revolution Celebrate National Award Winners at the 134th Continental Congress in Washington, DC

WASHINGTON, July 3, 2025 /PRNewswire/ -- Saturday, June 28 marked the final evening ceremony of the Daughters of the American Revolution (DAR) 134th Continental Congress...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrograms

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers